The Prognostic Role and Relationship between E2F1 and SV40 in Diffuse Large B-Cell Lymphoma of Egyptian Patients

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphomas worldwide. The pathogenesis of lymphomas is not yet well understood. SV40 induces malignant transformation by the large T-antigen (L-TAG) and promotes transformation by binding and inactivating p53 and pRb. L-TAG can bind pRb promoting the activation of the E2F1 transcription factor, thus inducing the expression of genes required for the entry to the S phase and leading to cell transformation. This immunohistochemical study was conducted to assess the prognostic role and relationship of SV40 L-TAG and E2F1 in diffuse large B-cell lymphoma (DLBCL) of Egyptian patients. This retrospective study was conducted on 105 tissue specimens including 20 follicular hyperplasia and 85 DLBCL cases. SV40 L-TAG was identified in 3/85 (4%) of DLBCL. High Ki-67 labeling index (Ki-67 LI) and apoptotic count were associated with high E2F1 expression (p<0.001 for all). No significant association was reached between E2F1 and SV40. E2F1 expression proved to be the most and first independent prognostic factor on overall survival of DLBCL patients (HR = 5.79, 95% CI = 2.3–14.6, and p<0.001). Upregulation of E2F1 has been implicated in oncogenesis, prognosis, and prediction of therapeutic response but is not seemingly to have a relationship with the accused SV40.

E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer

“…However, E2F1 overexpression is known to contribute to the development and progression of OC, and this role is mediated by the p53-dependent apoptotic pathway and PI3K/AKT signaling pathway and microRNA activity (13, 31). More and more studies revealed that E2F1 overexpression could produce more aggressive tumors with a high proliferation rate and chemoresistance (32–34). In our study, ONCOMINE and GEPIA datasets revealed that the expression of E2F1 was up-regulated in human OC, and E2F1 expression was linked with the clinical characteristics of patients with OC.…”

Prognostic role of pretreatment neutrophil-lymphocyte ratio in patients with diffuse large B-cell lymphoma treated with RCHOP

“…In recent years, many molecular signatures have been shown to have prognostic value in DLBCL, such as TIM-3, PD-1, and E2F1 levels. [ 32 , 33 ] However, molecular markers are often costly and inefficient, making them unsuitable for clinical laboratories. By contrast, blood cell count is an inexpensive and easily available measure in daily clinical practice.…”

Pretreatment C-reactive protein was an independent prognostic factor for patients with diffuse large B-cell lymphoma treated with RCHOP

“…Furthermore, a number of molecular signatures have also shown prognostic roles, such as PD-1 and TIM-3 expression concentrations [25], E2F1 expression [26], nuclear and cytoplasmic NF-κB expression [27] and LincRNA-p21expression [28]. However, molecular marker is associated with high costs and time-consuming procedures and is not routinely available in most laboratories.…”